Headache is one of the top 10 reasons people in the U.S. go to the doctor. With a prevalence this high, it is no surprise that all neurology exams have multiple questions on headache. There are nuances to headache diagnoses that neurologists must understand, and that test writers love to bring up. In this chapter, you will review the most commonly tested headache types, imaging, and treatments.

Authors: Andrew Levin MD, Brian Hanrahan MD, Steven Gangloff MD

Chapter Multimedia Content

Flashcards
Question Bank
Table of Contents

Table of Contents

Primary Headache Disorders

Migraine

  • Epidemiology:
    • Pediatric: Slightly more common in boys
    • After puberty: 3x more common in women (18% vs 6%)
    • No gender predilection after age 65
  • Diagnostic criteria:

A. At least 5 attacks 
B. Headaches lasting 4-72 hours
C. At least two of the following characteristics:
       1. Unilateral symptoms
       2. Pulsing/throbbing quality
       3. Moderate/severe pain intensity
       4. Worsened pain with activity.
D. At least one of the following:
       1. Nausea/vomiting
       2. photophobia/phonophobia. 

A. At least two attacks fulfilling criteria B and C
B. One or more of the following fully reversible aura symptoms:
     1. Visual
     2. Sensory
     3. Speech and/or language
     4. Motor
     5. Brainstem
     6. Retinal
C. At least three of the following six characteristics:
     1. At least one aura symptom spreads gradually over ≥5 minutes
     2. Two or more aura symptoms occur in succession
     3. Each individual aura symptom lasts 5-60 minutes
     4. At least one aura symptom is unilateral
     5. At least one aura symptom is positive
     6. The aura is accompanied, or followed within 60 minutes, by headache

  • At least two auras, one of which is fully reversible motor weakness.
  • Can be sporadic or familial.
  • Familial Type 1: Caused by an autosomal dominant mutation to CACNA1a gene (P/Q calcium channel) on chromosome 19.
    • CACNA1a gene mutations can also cause episodic cerebellar ataxia.
  • Familial Type 2: Associated with ATP1A2 (Na-K ATPase channel) on chromosome 1. 
  • Familial Type 3: Mutation to SCN1a on chromosome 2.
      • SCN1a gene mutations can also cause genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome.
  • Formerly called “basilar” migraine
  • At least two brainstem symptoms for aura:
    1. dysarthria
    2. vertigo
    3. tinnitus
    4. hyperacusis
    5. diplopia
    6. ataxia
    7. decreased level of arousal
  • Migraine with ≥15 headache days a month, for >3 months.
  • The only FDA-approved medication for chronic migraine is botulinum injection (onabotulinumtoxinA).
  • Migraine with visual symptoms, such as flashing or shimmering lights.
  • It will sound very similar to migraine with aura, except the visual disturbance is monocular.
  • Pathophysiology:

    • Release of vasoactive peptides (calcitonin gene-related peptide (CGRP), neurokinin A, substance P).
    • Vasodilation and sterile inflammation in dural vessels, leading to activation of first-order trigeminal afferents which presents clinically by throbbing head pain.
    • The migraine aura occurs due to spreading depolarilzations.

Abortive Migraine Treatment

  • Abortive migraine therapy should be considered in patients with severe headache episodes regardless of frequency.

Triptans: 

  • First-line therapy with Level A evidence. 
  • Mechanism of action: Agonists at 5HT-1B (meningeal blood vessel constriction) and 5HT-1D (prevents nociceptive neuropeptide release).
  • Contraindicated in patients with a history of coronary artery disease, stroke, hemiplegic migraine and migraine with brainstem aura.
  • Common side effects: drowsiness, a sensation of warmth, paresthesias, dizziness, and nausea.
  • Sumatriptan
  • Zolmitriptan
  • Rizatriptan
  • Almotriptan
  • Eletriptan.
  • Naratriptan
  • Frovatriptan
    • Has the longest half-life (25h) and used often in patients for menstrual-related migraines.

Ditans (Lasmiditan):

    • Mechanism of action: 5HT-1F receptor agonism (receptors on trigeminal ganglion)
    • Lasmiditan (oral tablet) is the only drug currently on the market.
    • Not contraindicated for patients with coronary artery disease or stroke.

CGRP antagonists (Rimegepant, Ubrogepant):

  • Mechanism of action: Inhibition of CGRP receptors.
  • Side effects may include nausea, tiredness, and dry mouth.
  • Ubrogepant is contraindicated with concomitant use of strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, etc.)

NSAIDs: ibuprofen, ketorolac, naproxen, flurbiprofen, diclofenac

Anti-emetics: prochlorperazine, metoclopramide, promethazine

Prophylactic Migraine Treatment

  • Prophylactic migraine therapy is indicated when symptoms occur more than 4 headaches, or 8 headache days, a month.
  • Metoprolol (level A evidence)
  • Propranolol (level A evidence)
  • Timolol (level A evidence)
  • Nadolol (level B evidence)
  • Atenolol (level B evidence)

Should be avoided in patients with asthma and Raynaud’s phenomenon.

  • Topiramate (level A evidence): One of the most common first-line therapies. Side effect profile includes calcium phosphate stones, paresthesias, cognitive symptoms, fatigue, and weight loss. (Level A evidence)
    • Risk for cleft lip and low birth weight if used during pregnancy. 
  • Valproic acid (level A evidence): Adverse effects include ataxia, sedation, tremor, nausea/vomiting. Monitor liver enzymes.
    • Should be avoided during pregnancy.
  • Gabapentin (level U evidence): May be helpful for comorbid tremor, RLS, and neuropathy.
    • Side effects include dizziness and sedation.
  • Tricyclic antidepressants (TCAs):
    • Adverse effects may include anticholinergic side effects (dry mouth, constipation, weight gain, orthostatic hypotension, and sedation).
    • Amitriptyline (level B evidence)
    • Nortriptyline (metabolite of amitriptyline; less side effects)
    • Imipramine
    • Protriptyline (level U evidence; less sedation; may be activating)
  • SSRIs/SNRIs
    1. Venlafaxine (level B evidence)
    2. Duloxetine
    3. Fluoxetine (level U evidence)
  • Novel (approved 2018) class of monoclonal antibody medications for migraine prevention.
      • The antibodies block CGRP, which is an important vasoactive peptide involved in the migraine cascade.
  • First drug developed specifically for migraine prevention.
  • Once monthly injections:
    • Fremanezumab (can also be given quarterly)
    • Erenumab (side effect of constipation)
    • Glacanezumab
  • Quarterly IV infusion
    • Eptinezumab
  • Rimegepant (approved for both Migraine prevention and abortion)
  • Butterbur
    • An herbal supplement from a shrub (level A evidence).
    • Side effects include upset stomach and diarrhea.
  • Magnesium (oxide, citrate, sulfate)
  • Coenzyme Q10
  • Riboflavin (Vitamin B2)
  • Supraorbital nerve stimulation
  • Percutaneous sphenopalatine ganglion stimulation
  • Transcranial magnetic stimulation

Status Migrainosus Treatment

  • If headache has persisted >72 hours, it is considered status migrainosus, and warrants aggressive treatment. 
  • Intravenous infusion of antiemetics, ketorolac, valproic acid, magnesium, and steroids can be tried. 

Dihydroergotamine (DHE): 

    • Multi-day in-hospital infusion to break status migrainosus. 
    • Contraindications: peripheral vascular disease, coronary artery disease, severe hypertension, angina, recent triptan use within 24 hours, pregnancy, severe liver disease. 

Migraine in women 

  • Women of child-bearing age who have migraine with aura have a two-fold increase in the relative risk of stroke.
    • Six-fold increase in risk if they also use estrogen-containing OCPs.
    • Nine-fold increase risk of stroke if they use estrogen-containing OCPs and also smoke.
  • Many patients have menstrual-related headaches which occur when estrogen levels drop around the time of menstration.
    • This is why patients report worse headache frequency during perimenopause and improved headache frequency during the 2nd and 3rd trimesters of pregnancy.
    • Most perimenopause patients have an improvement in headache frequency when they enter menopause.
  • Most abortive and preventive treatments carry an increased risk of fetal harm.
    • Butalbital, codeine, triptans, topiramate, and valproic acid should all be avoided
      due to risks to the fetus. 
  • Acetaminophen is the first-line headache medication in pregnancy.
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used only in the first or
      second trimester.
  • Other treatment options include metoclopramide, magnesium, and occipital nerve blocks.

Paroxysmal Hemicrania:

    • Presents with severe, frequent (~15-40 daily), brief (<30 minutes), unilateral attacks (V1 distribution) with autonomic features.
    • The pain is usually localized around the eye, temple, and forehead and is often associated with autonomic symptoms including lacrimation, ptosis, rhinorrhea, and facial flushing.
    • It is more common in women.
    • Treatment: Indomethacin.
      • Response to indomethacin is so classic that it is part of the diagnostic criteria.

Cluster Headache:

    • Presents with recurrent, severe unilateral headaches around the eye with autonomic symptoms.
    • Episodes usually last 15-180 minutes and occur up to 8 times in a day.
    • Episodes often have circadian and/or circannual patterns.
    • Cluster headaches are seen more often in men and smokers.
    • Treatment:
      • Abortive therapy is high-flow oxygen, injectable sumatriptan, or nasal zolmitriptan.
      • Prophylactic therapy options include verapamil (calcium channel blocker), lithium, valproic acid, melatonin and galcanezumab.
        • Consider a short-term treatment of steroids as a “cycle breaker” during the latency period of preventative therapy after initiation if needed. 

Tension Headache

  • Epidemiology
    • Most common primary headache disorder

  • Diagnostic criteria
    1. Can be infrequent (At least 10 episodes of headache occurring on <1 day/month on average (<12 days/year)) or frequent (At least 10 episodes of headache occurring on 1-14 days/month on average for >3 months (≥12 and <180 days/year)).
    2. Headaches last from 30 minutes to 7 days
    3. Must have at least two of the following four characteristics:
      1. bilateral location
      2. pressing or tightening (non-pulsating) quality
      3. mild or moderate intensity
      4. not aggravated by routine physical activity such as walking or climbing stairs
    4. Must have both of the following:
      1. no nausea or vomiting
      2. no more than one of photophobia or phonophobia
  • Treatment
    • Abortive: NSAIDs, Tylenol, caffeine
    • Preventive: amitriptyline, nortriptyline, venlafaxine, mirtazapine, biofeedback

 

Log in to View the Remaining 60-90% of Page Content!

 
 

New here? Get started!

(Or, click here to learn about our institution/group pricing)
   

1 Month Plan

Full Access Subscription
$142.49
$ 94
99
1 Month
  • Access to all chapters
  • Access to all images and cases
  • Access to all flashcards
  • Access to Full Question Bank
Choose Plan

3 Month Plan

Full Access Subscription
$224.98
$ 144
97
3 Months
  • Access to all chapters
  • Access to all images and cases
  • Access to all flashcards
  • Access to Full Question Bank
Choose Plan

1 Year Plan

Full Access Subscription
$538.47
$ 338
98
1 Year
  • Access to all chapters
  • Access to all images and cases
  • Access to all flashcards
  • Access to Full Question Bank
Choose Plan
Popular

Table of Contents

Table of Contents